L.R. Kelland
CRC Centre for Cancer Therapeutics
Institute of Cancer Research
Sutton
Surrey
UK
Name/email consistency: low
- Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer. Kelland, L.R., Smith, V., Valenti, M., Patterson, L., Clarke, P.A., Detre, S., End, D., Howes, A.J., Dowsett, M., Workman, P., Johnston, S.R. Clin. Cancer Res. (2001)
- Telomerase: biology and phase I trials. Kelland, L.R. Lancet Oncol. (2001)
- Telomerase inhibitors: targeting the vulnerable end of cancer?. Kelland, L.R. Anticancer. Drugs (2000)
- An update on satraplatin: the first orally available platinum anticancer drug. Kelland, L.R. Expert. Opin. Investig. Drugs (2000)
- Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status. Kelland, L.R. Expert. Opin. Investig. Drugs (2000)
- Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance. Kelland, L.R., Sharp, S.Y., O'Neill, C.F., Raynaud, F.I., Beale, P.J., Judson, I.R. J. Inorg. Biochem. (1999)
- Meeting report on 8th International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Kelland, L.R. J. Inorg. Biochem. (1999)
- Small molecule anticancer drugs. Kelland, L.R. IDrugs (1999)
- NCI-EORTC - 10th Symposium - New approaches and cellular targets. Kelland, L. IDrugs (1998)
- Signal transduction pathways. Kelland, L. IDrugs (1998)
- DNA-interactive agents. Kelland, L. IDrugs (1998)